EWSR1/EWS Monoclonal Antibody
- Size: 100ul
- Application: WB, IHC-P, IF(ICC), IHC
- Reactivity: Human, Mouse, Rat
- Predicted Reactivity:
-
Datasheet Tech Support
IMAGES
PRODUCT DETAILS
SPECIFICATIONS |
|
---|---|
PRODUCT NAME |
EWSR1/EWS Monoclonal Antibody |
CONJUGATION |
Unconjugated |
HOST |
Rabbit |
SOURCE |
Synthetic Peptide within N terminal human EWSR1/EWS. |
IMMUNOGEN RANGE |
|
CLONALITY |
Monoclonal |
ISOTYPE |
IgG |
CONCENTRATION |
1ug/ul |
PURIFICATION |
Purified by Protein A. |
STORAGE BUFFER |
Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. |
STORAGE CONDITION |
Store at -20°C for 12 months.. |
TARGET |
|
---|---|
GENE ID |
|
SUBCELLULAR LOCATION |
Cytoplasm, Nucleus, Plasma membrane |
SYNONYMS |
bK984G1.4 antibody, bK984G1.4 Ewing sarcoma breakpoint region 1 protein antibody, Ewing sarcoma breakpoint region 1 antibody, Ewing sarcoma breakpoint region 1 protein antibody, Ewings sarcoma EWS Fli1 type 1 oncogene antibody, EWS antibody, EWS oncogene antibody, EWS RNA binding protein 1 antibody, EWS_HUMAN antibody, EWSR 1 antibody, Ewsr1 antibody, EWSR1 protein antibody, RNA binding protein EWS antibody, RNA-binding protein EWS antibody |
BACKGROUND |
EWS is a nuclear RNA-binding protein. As a result of chromosome translocation, the EWS gene is fused to a variety of transcription factors, including ATF-1 in human neoplasias. In the Ewing family of tumors, the N-terminal domain of EWS is fused to the DNA-binding domain of various ETS transcription factors, including Fli-1, Erg, ETV1, E1AF and FEV. The EWS/Fli-1 chimeric protein acts as a more potent transcriptional activator than Fli-1 and can promote cell transformation. Two functional regions have been identified in EWS; an amino-terminal region (domain A), that has little transactivation activity but transforms efficiently when fused to Fli-1, and a distal region (domain B), which shows transactivation activity but transforms less efficiently when fused to Fli-1. |
APPLICATION DILUTION |
WB(1:300-1000), IHC-P(1:200-400), IF(ICC)(1:50-200), IHC() |